KALA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KALA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-13), Kala Bio's share price is $6.90. Kala Bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.85. Hence, Kala Bio's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Kala Bio's Price-to-Operating-Cash-Flow or its related term are showing as below:
Kala Bio's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-2.83. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.85.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 49.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 32.60% per year.
During the past 9 years, Kala Bio's highest 3-Year average Operating Cash Flow per Share Growth Rate was 49.00% per year. The lowest was -32.40% per year. And the median was 11.70% per year.
The historical data trend for Kala Bio's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kala Bio Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Kala Bio Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Kala Bio's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kala Bio's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Kala Bio's Price-to-Operating-Cash-Flow falls into.
Kala Bio's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 6.90 | / | -11.853 | |
= |
Kala Bio's Share Price of today is $6.90.
Kala Bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.85.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of Kala Bio's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Todd Bazemore | officer: Chief Operating Officer | C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
Romulus K Brazzell | officer: Chief Medical Officer | C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Eric Trachtenberg | officer: See Remarks | 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517 |
Darius Kharabi | officer: CHIEF BUSINESS OFFICER | C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472 |
Mark T Iwicki | director, officer: Chief Executive Officer | 84 WATERFORD DRIVE, MARLBOROUGH MA 01752 |
Mary Reumuth | officer: Chief Financial Officer | 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453 |
Marjan Farid | director | C/O KALA PHARMACEUTICALS, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON MA 02476 |
Ra Capital Healthcare Fund Lp | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Mark S. Blumenkranz | director | C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111 |
Hongming Chen | officer: Chief Scientific Officer | 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453 |
C. Daniel Myers | director | 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Gregory Grunberg | director | 100 BEAVER STREET, WALTHAM MA 02453 |
Rajeev M. Shah | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Peter Kolchinsky | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ra Capital Management, L.p. | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By PurpleRose PurpleRose • 08-18-2022
By Marketwired • 08-04-2023
By PurpleRose PurpleRose • 08-08-2022
By sperokesalga sperokesalga • 04-12-2023
By GuruFocusNews GuruFocusNews • 07-08-2022
By sperokesalga sperokesalga • 05-09-2023
By GuruFocusNews GuruFocusNews • 07-07-2022
By Marketwired • 09-05-2023
By Marketwired • 08-02-2023
By Marketwired • 07-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.